SCARB1

Summary

SCARB1 (scavenger receptor class B member 1, HGNC:1664) is a protein-coding gene on chromosome 12q24.31, encoding Scavenger receptor class B member 1 (Q8WTV0). Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells.

The protein encoded by this gene is a plasma membrane receptor for high density lipoprotein cholesterol (HDL). The encoded protein mediates cholesterol transfer to and from HDL. In addition, this protein is a receptor for hepatitis C virus glycoprotein E2 and facilitates cell entry by the virus, SARS-CoV2.

Source: NCBI Gene 949 — RefSeq curated summary.

At a glance

• GWAS associations: 66
• Clinical variants (ClinVar): 204 total — 1 pathogenic
• Druggable target: yes — 2 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_005505

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:1664
Approved symbol	SCARB1
Name	scavenger receptor class B member 1
Location	12q24.31
Locus type	gene with protein product
Status	Approved
Aliases	SRB1, CLA-1, CLA1, SR-BI
Ensembl gene	ENSG00000073060
Ensembl biotype	protein_coding
OMIM	601040
Entrez	949

Gene structure

Transcript identifiers

Ensembl transcripts: 45 — 31 protein_coding, 6 retained_intron, 5 nonsense_mediated_decay, 3 protein_coding_CDS_not_defined

ENST00000261693, ENST00000339570, ENST00000415380, ENST00000535005, ENST00000538291, ENST00000539320, ENST00000541661, ENST00000544327, ENST00000545305, ENST00000545493, ENST00000546215, ENST00000679605, ENST00000679955, ENST00000680556, ENST00000680596, ENST00000680926, ENST00000680982, ENST00000681117, ENST00000681499, ENST00000681555, ENST00000681686, ENST00000681788, ENST00000877826, ENST00000877827, ENST00000877828, ENST00000877829, ENST00000877830, ENST00000877831, ENST00000877832, ENST00000877833, ENST00000877834, ENST00000877835, ENST00000877836, ENST00000877837, ENST00000936307, ENST00000936308, ENST00000936309, ENST00000936310, ENST00000936311, ENST00000936312, ENST00000964690, ENST00000964691, ENST00000964692, ENST00000964693, ENST00000964694

RefSeq mRNA: 11 — MANE Select: NM_005505 NM_001082959, NM_001367981, NM_001367982, NM_001367983, NM_001367984, NM_001367985, NM_001367986, NM_001367987, NM_001367988, NM_001367989, NM_005505

CCDS: CCDS45008, CCDS91769, CCDS91770, CCDS91771, CCDS9259

Canonical transcript exons

ENST00000261693 — 13 exons

Exon	Start	End
ENSE00001329956	124863595	124863864
ENSE00003474911	124811870	124811965
ENSE00003524630	124800124	124800242
ENSE00003526102	124810174	124810289
ENSE00003544724	124814973	124815114
ENSE00003577732	124782683	124782811
ENSE00003581233	124787406	124787457
ENSE00003607572	124795195	124795268
ENSE00003608768	124786357	124786503
ENSE00003635066	124807761	124807927
ENSE00003673083	124817550	124817707
ENSE00003678576	124814202	124814405
ENSE00003681386	124776856	124778586

Expression profiles

Bgee: expression breadth ubiquitous, 244 present calls, max score 99.70.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 81.3898 / max 6282.2535, expressed in 1790 samples.

FANTOM5 promoters (4 alternative TSS)

Promoter ID	TPM avg	Samples expressed
134035	58.6329	1727
134037	12.4831	1672
134038	6.6609	1671
134036	3.6130	1323

Top tissues by expression

289 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right adrenal gland cortex	UBERON:0035827	99.70	gold quality
right adrenal gland	UBERON:0001233	99.68	gold quality
left adrenal gland	UBERON:0001234	99.68	gold quality
adrenal cortex	UBERON:0001235	99.67	gold quality
adrenal tissue	UBERON:0018303	99.66	gold quality
left adrenal gland cortex	UBERON:0035825	99.65	gold quality
adrenal gland	UBERON:0002369	99.44	gold quality
right lobe of liver	UBERON:0001114	98.64	gold quality
liver	UBERON:0002107	96.60	gold quality
left ovary	UBERON:0002119	96.26	gold quality
right ovary	UBERON:0002118	96.03	gold quality
putamen	UBERON:0001874	95.64	gold quality
caudate nucleus	UBERON:0001873	95.44	gold quality
omental fat pad	UBERON:0010414	95.42	gold quality
peritoneum	UBERON:0002358	95.36	gold quality
adipose tissue of abdominal region	UBERON:0007808	95.14	gold quality
subcutaneous adipose tissue	UBERON:0002190	94.90	gold quality
placenta	UBERON:0001987	94.56	gold quality
adipose tissue	UBERON:0001013	93.82	gold quality
nucleus accumbens	UBERON:0001882	93.79	gold quality
right frontal lobe	UBERON:0002810	93.11	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	92.81	gold quality
gall bladder	UBERON:0002110	92.78	gold quality
connective tissue	UBERON:0002384	92.70	gold quality
ovary	UBERON:0000992	92.32	gold quality
duodenum	UBERON:0002114	92.26	gold quality
amygdala	UBERON:0001876	92.18	gold quality
pigmented layer of retina	UBERON:0001782	91.65	gold quality
retina	UBERON:0000966	91.62	gold quality
stromal cell of endometrium	CL:0002255	91.47	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.55
E-MTAB-10137	no	496.59
E-GEOD-81383	no	158.48

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): CREB1, CUX1, DGKQ, ESR1, FOXO1, GLI1, HNF4A, IRF6, KLF4, KMT2A, KMT2B, MSR1, MYC, NR0B2, NR1H2, NR1H3, NR1H4, NR1I2, NR3C1, NR5A1, NR5A2, PPARA, PPARG, PREB, RXRA, SP1, SP3, SPI1, SREBF1, SREBF2, STAT1, STAT2

miRNA regulators (miRDB)

43 targeting SCARB1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-6867-5P	100.00	82.21	3464
HSA-MIR-223-3P	99.99	70.14	1140
HSA-MIR-4482-3P	99.98	72.50	3147
HSA-MIR-4650-5P	99.98	64.69	999
HSA-MIR-96-5P	99.95	72.80	2140
HSA-MIR-185-3P	99.95	67.01	1743
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-345-3P	99.89	70.23	1421
HSA-MIR-4319	99.76	69.83	2586
HSA-MIR-3934-3P	99.76	65.51	1351
HSA-MIR-556-3P	99.74	68.75	1203
HSA-MIR-4306	99.72	70.50	3630
HSA-MIR-670-5P	99.67	69.94	1565
HSA-MIR-24-3P	99.59	69.97	1934
HSA-MIR-3682-3P	99.58	67.63	865
HSA-MIR-766-5P	99.47	67.91	2225
HSA-MIR-125A-5P	99.36	70.59	1640
HSA-MIR-125B-5P	99.36	70.36	1662
HSA-MIR-4284	99.36	65.25	1293
HSA-MIR-149-5P	99.25	67.16	1315
HSA-MIR-4685-5P	99.25	65.99	1563
HSA-MIR-6837-5P	99.25	65.47	1632
HSA-MIR-661	99.09	65.94	2062
HSA-MIR-328-5P	99.08	64.65	1000
HSA-MIR-939-3P	98.97	65.07	2347
HSA-MIR-455-3P	98.94	67.68	878
HSA-MIR-936	98.87	70.51	1124
HSA-MIR-4755-3P	98.77	65.59	1915
HSA-MIR-6885-5P	98.71	64.33	902
HSA-MIR-6811-3P	98.62	66.54	944

Literature-anchored findings (GeneRIF, showing 40)

• binding to high density lipoprotein activates endothelial nitric-oxide synthase in a ceramide-dependent manner (PMID:11792700)
• SR-BI is a phagocytosis-inducing PS receptor of Sertoli cells. (PMID:12016218)
• PDZK1 or other PDZ domain proteins may play an important role in regulating SR-BI cell surface expression and hence reverse cholesterol transport. (PMID:12119305)
• SR-BI regulation of cholesteryl ester uptake is affected by binding to APOE in human cells (PMID:12138091)
• EDL mediates both HDL binding and uptake, and the selective uptake of HDL-CE, independently of lipolysis and CLA-1. (PMID:12164779)
• Testosterone up-regulates scavenger receptor BI mRNA in macrophages (PMID:12207878)
• There is an association between HaeIII polymorphism of scavenger receptor class B type I gene and plasma HDL-cholesterol concentration in patients with CAD. (PMID:12227853)
• basal and SR-BI-stimulated free cholesterol efflux to HDL and liposomes and SR-BI-mediated selective uptake of HDL cholesteryl ester are not affected by caveolin-1 expression (PMID:12562842)
• binds and internalizes lipopolysasccharides and lipoproteins and is a orthologue of rodent SR-BI (PMID:12651854)
• carriers of the minority allele, 1/2, of the scavenger receptor class B type I gene are more susceptible to the presence of saturated fatty acids in the diet because of a greater increase in LDL cholesterol (PMID:12663276)
• Transcriptional activation of SR-BI is stimulated by peroxisome proliferator-activated receptor gamma and hepatocyte nuclear factor 4alpha. (PMID:12763030)
• SR-BI gene variation modulates the lipid profile, particularly in type 2 diabetes, contributing to the metabolic abnormalities. (PMID:12788901)
• Genetic variants in the HDL receptor, SR-B1, may be an important determinant of abnormal lipoproteins in women and may confer particular susceptibility to coronary artery disease. (PMID:12807968)
• SR-B1 is required for hepatitis C virus infection of CD81-expressing hepatic cells (PMID:12913001)
• CD36 and SR-BI are receptors for hypochlorite-modified low density lipoprotein (PMID:12968020)
• Polymorphisms of the HDL receptor gene associated with HDL cholesterol levels in diabetic kindred (PMID:14566094)
• human intestine possesses a developmental and regional SR-BI pattern of distribution (PMID:14676281)
• SR-BI-facilitated diffusion is not dependent on pre-beta-high density lipoprotein interaction with human chymase (PMID:14701812)
• SR-BI-mediated cholesteryl ester-selective uptake and efflux of unesterified cholesterol is regulated by HDL (PMID:14718538)
• alternative spliced sr-bI (SR-BII) may influence cellular cholesterol trafficking and homeostasis in a manner that is distinct from SR-BI. (PMID:14726519)
• SR-BI levels in macrophages are responsive to changes in intracellular sterol content and that these sterol-associated changes are not mediated by LXR and are unlikely to be mediated by an SREBP pathway (PMID:14967816)
• plays a major role in the clearance of apoptotic cells from the thymus. (PMID:15072554)
• The reciprocal inhibition of SR-BI and ABCA1 by BLT-4 and glyburide raises the possibility that these proteins may share similar or common steps in their mechanisms of lipid transport. (PMID:15102890)
• Scavenger receptor BI function is not only crucial for cholesterol delivery to the liver but is also important for cholesterol efflux at the vessel wall [review]. (PMID:15166784)
• SR-BI is associated with membrane rafts devoid of caveolin and its expression affects intracellular lipid binding and lipid sensor proteins in HepG2 cells (PMID:15226391)
• uptake of lipoprotein-associated phosphatidylcholine by the cerebrovasculature via scavenger receptor class B, type I could generate a pool of lipids (PMID:15342124)
• endogenous expression of SR-BI/CLA-1 was suppressed by exposure to growth hormone or IGF-I in cultured HepG2 cells (PMID:15345670)
• SR-B1 is not required for apolipoprotein A-1-mediated endothelial cholesterol efflux from vascular endothelial cells. (PMID:15492319)
• analysis of uptake of individual HDL particles in living cells via the scavenger receptor class B type I (PMID:15509885)
• SR-BI plays a key role in SAA metabolism through its ability to interact with and internalize SAA and SAA influences HDL cholesterol metabolism through its inhibitory effects on SR-BI-mediated selective lipid uptake (PMID:15561721)
• CLA-1 functions as an endocytic SAA receptor and is involved in SAA-mediated cell signaling events associated with the immune-related and inflammatory effects of SAA (PMID:15576377)
• HDL-mediated enhancement of HCVpp entry involves a complex interplay between SR-BI, HDL, and HCV envelope glycoproteins (PMID:15632171)
• plausible genetic interaction between the CLA-1 exon 8 gene polymorphism and the risk of coroanry heart disease in males (PMID:15681296)
• at low levels of high density lipoproteins, oxidative stress causes the relocation of eNOS away from caveolae, which turns on SR-BI-induced apoptosis and rapidly clears damaged cells to prevent further inflammatory damage to neighboring cells (PMID:15749707)
• SR-BI is expressed in a cell-specific fashion in the initial & terminal steps of reverse cholesterol transport. It may be physiologically relevant and have distinct tissue-specific functions. (PMID:15970294)
• SR-BI is expressed in a cell-specific fashion in the initial & terminal steps of reverse cholesterol transport. It may be physiologically relevant and have distinct tissue-specific functions. (PMID:15979078)
• Serum amyloid A has a role in promoting cholesterol efflux mediated by scavenger receptor B-I (PMID:16120612)
• SR-BI-mediated supply of cholesterol, the substrate for bile acid synthesis. (PMID:16168958)
• only lipid-bound apoE promotes SR-BI-mediated cholesterol efflux and that the amino-terminal region of residues 1-165 of apoE is sufficient for both receptor binding and cholesterol efflux (PMID:16185081)
• vitamin E intestinal absorption is, at least in part, mediated by SR-BI (PMID:16380385)

Cross-species orthologs

8 orthologs

Organism	Symbol	Gene ID
danio_rerio	scarb1	ENSDARG00000101557
mus_musculus	Scarb1	ENSMUSG00000037936
rattus_norvegicus	Scarb1	ENSRNOG00000000981
drosophila_melanogaster	emp	FBGN0010435
drosophila_melanogaster	CG10345	FBGN0027562
drosophila_melanogaster	CG3829	FBGN0035091
drosophila_melanogaster	dsb	FBGN0035290
drosophila_melanogaster	CG40006	FBGN0058006

Paralogs (2): CD36 (ENSG00000135218), SCARB2 (ENSG00000138760)

Protein

Protein identifiers

Scavenger receptor class B member 1 — Q8WTV0 (reviewed: Q8WTV0)

Alternative names: CD36 and LIMPII analogous 1, CD36 antigen-like 1, Collagen type I receptor, thrombospondin receptor-like 1, SR-BI

All UniProt accessions (10): Q8WTV0, A0A0S2Z3I2, A0A7P0T913, A0A7P0T9B3, A0A7P0T9I2, A0A7P0Z4E3, A0A7P0Z4J8, B7ZKQ9, F5H4X0, F5H5E8

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for different ligands such as phospholipids, cholesterol ester, lipoproteins, phosphatidylserine and apoptotic cells. Receptor for HDL, mediating selective uptake of cholesteryl ether and HDL-dependent cholesterol efflux. Also facilitates the flux of free and esterified cholesterol between the cell surface and apoB-containing lipoproteins and modified lipoproteins, although less efficiently than HDL. May be involved in the phagocytosis of apoptotic cells, via its phosphatidylserine binding activity. (Microbial infection) Acts as a receptor for hepatitis C virus in hepatocytes and appears to facilitate its cell entry. Binding between SCARB1 and the hepatitis C virus glycoprotein E2 is independent of the genotype of the viral isolate. (Microbial infection) Mediates uptake of M.fortuitum, E.coli and S.aureus. (Microbial infection) Facilitates the entry of human coronavirus SARS-CoV-2 by acting as an entry cofactor through HDL binding.

Subunit / interactions. The C-terminal region binds to PDZK1. (Microbial infection) Interacts with hepatitis C virus E1:E2 glycoproteins.

Subcellular location. Cell membrane. Membrane. Caveola.

Tissue specificity. Widely expressed.

Post-translational modifications. N-glycosylated. The six cysteines of the extracellular domain are all involved in intramolecular disulfide bonds.

Polymorphism. Genetic variations in SCARB1 define the high density lipoprotein cholesterol level quantitative trait locus 6 (HDLCQ16) [MIM:610762].

Miscellaneous. May be due to a competing donor splice site.

Similarity. Belongs to the CD36 family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q8WTV0-1	3	yes
Q8WTV0-2	1, SR-BI
Q8WTV0-3	2, SR-BII
Q8WTV0-4	4, SR-BIII
Q8WTV0-5	5, SR-BI.2, SR-BII

RefSeq proteins (11): NP_001076428, NP_001354910, NP_001354911, NP_001354912, NP_001354913, NP_001354914, NP_001354915, NP_001354916, NP_001354917, NP_001354918, NP_005496* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002159	CD36_fam	Family
IPR005428	CD36/SCARB1/SNMP1	Family

Pfam: PF01130

UniProt features (33 total): glycosylation site 9, sequence variant 7, splice variant 4, topological domain 3, modified residue 3, transmembrane region 2, sequence conflict 2, chain 1, disulfide bond 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8WTV0-F1	84.25	0.65

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 493, 393, 458, 462

Disulfide bonds (1): 251–384

Glycosylation sites (9): 212, 227, 255, 310, 330, 383, 102, 108, 173

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-3000471	Scavenging by Class B Receptors
R-HSA-8964011	HDL clearance

MSigDB gene sets: 0 (showing top):

GO Biological Process (33): endothelial cell proliferation (GO:0001935), cholesterol catabolic process (GO:0006707), positive regulation of endothelial cell migration (GO:0010595), obsolete positive regulation of nitric oxide mediated signal transduction (GO:0010750), positive regulation of triglyceride biosynthetic process (GO:0010867), positive regulation of cholesterol storage (GO:0010886), regulation of phosphatidylcholine catabolic process (GO:0010899), phospholipid transport (GO:0015914), lipopolysaccharide transport (GO:0015920), detection of lipopolysaccharide (GO:0032497), cholesterol efflux (GO:0033344), high-density lipoprotein particle remodeling (GO:0034375), plasma lipoprotein particle clearance (GO:0034381), low-density lipoprotein particle clearance (GO:0034383), high-density lipoprotein particle clearance (GO:0034384), vitamin transmembrane transport (GO:0035461), wound healing (GO:0042060), vasodilation (GO:0042311), cholesterol homeostasis (GO:0042632), blood vessel endothelial cell migration (GO:0043534), recognition of apoptotic cell (GO:0043654), reverse cholesterol transport (GO:0043691), adhesion of symbiont to host (GO:0044406), regulation of phagocytosis (GO:0050764), high density lipoprotein particle mediated signaling (GO:0055097), triglyceride homeostasis (GO:0070328), cholesterol import (GO:0070508), intestinal lipid absorption (GO:0098856), positive regulation of sphingolipid mediated signaling pathway (GO:1902070), lipid transport (GO:0006869), cholesterol transport (GO:0030301), lipopolysaccharide-mediated signaling pathway (GO:0031663), symbiont entry into host cell (GO:0046718)

GO Molecular Function (14): lipopolysaccharide binding (GO:0001530), amyloid-beta binding (GO:0001540), virus receptor activity (GO:0001618), phosphatidylserine binding (GO:0001786), lipopolysaccharide immune receptor activity (GO:0001875), scavenger receptor activity (GO:0005044), 1-phosphatidylinositol binding (GO:0005545), high-density lipoprotein particle binding (GO:0008035), lipid binding (GO:0008289), low-density lipoprotein particle binding (GO:0030169), apolipoprotein binding (GO:0034185), apolipoprotein A-I binding (GO:0034186), high-density lipoprotein particle receptor activity (GO:0070506), protein binding (GO:0005515)

GO Cellular Component (9): lysosome (GO:0005764), lysosomal membrane (GO:0005765), plasma membrane (GO:0005886), caveola (GO:0005901), cell surface (GO:0009986), endocytic vesicle membrane (GO:0030666), extracellular exosome (GO:0070062), cytoplasm (GO:0005737), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Binding and Uptake of Ligands by Scavenger Receptors	1
Plasma lipoprotein clearance	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
endothelial cell migration	2
lipid transport	2
plasma lipoprotein particle clearance	2
phospholipid binding	2
lipoprotein particle binding	2
binding	2
epithelial cell proliferation	1
cholesterol metabolic process	1
sterol catabolic process	1
alcohol catabolic process	1
regulation of endothelial cell migration	1
positive regulation of cell migration	1
regulation of triglyceride biosynthetic process	1
triglyceride biosynthetic process	1
positive regulation of lipid biosynthetic process	1
positive regulation of triglyceride metabolic process	1
cholesterol storage	1
positive regulation of lipid storage	1
regulation of cholesterol storage	1
phosphatidylcholine catabolic process	1
regulation of phospholipid catabolic process	1
regulation of phosphatidylcholine metabolic process	1
organophosphate ester transport	1
carbohydrate derivative transport	1
detection of molecule of bacterial origin	1
response to lipopolysaccharide	1
cholesterol transport	1
plasma lipoprotein particle remodeling	1
receptor-mediated endocytosis	1
multicellular organismal process	1
plasma lipoprotein particle disassembly	1
regulation of plasma lipoprotein particle levels	1
low-density lipoprotein particle disassembly	1
vitamin transport	1
transmembrane transport	1
response to wounding	1
tissue regeneration	1
blood vessel diameter maintenance	1
sterol homeostasis	1

Protein interactions and networks

STRING

5200 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SCARB1	APOA1	P02647	998
SCARB1	TLR4	O00206	997
SCARB1	TLR2	O60603	996
SCARB1	CD81	P18582	995
SCARB1	THBS1	P07996	994
SCARB1	CD47	Q08722	994
SCARB1	TLR6	Q9Y2C9	993
SCARB1	APOB	P04114	990
SCARB1	LYN	P07948	973
SCARB1	APOE	P02649	963
SCARB1	THBS2	P35442	950
SCARB1	FYN	P06241	941
SCARB1	TLR1	Q15399	941
SCARB1	CLDN1	O95832	934
SCARB1	ABCA1	O95477	933
SCARB1	NPC1L1	Q9UHC9	933

IntAct

98 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
SCARB1	rep	psi-mi:“MI:0915”(physical association)	0.660
CANX	PGRMC1	psi-mi:“MI:0914”(association)	0.570
KRTAP5-9	SCARB1	psi-mi:“MI:0915”(physical association)	0.560
KRTAP10-9	SCARB1	psi-mi:“MI:0915”(physical association)	0.560
SCARB1	KRTAP10-9	psi-mi:“MI:0915”(physical association)	0.560
SCARB1	CD81	psi-mi:“MI:0915”(physical association)	0.560
SCARB1	CSNK1D	psi-mi:“MI:0915”(physical association)	0.560
JUN	SCARB1	psi-mi:“MI:0915”(physical association)	0.560
APP	SCARB1	psi-mi:“MI:0915”(physical association)	0.560
CD81	C2orf72	psi-mi:“MI:0914”(association)	0.530
rep	AGPS	psi-mi:“MI:0914”(association)	0.530
FBXO2	TMEM131L	psi-mi:“MI:0914”(association)	0.530
TMEM30B	KLRG2	psi-mi:“MI:0914”(association)	0.530
DEFA1	MANBA	psi-mi:“MI:0914”(association)	0.530
CLGN	NPC1	psi-mi:“MI:0914”(association)	0.530
SCGB1D4	EGFR	psi-mi:“MI:0914”(association)	0.530
VAMP5	NBAS	psi-mi:“MI:0914”(association)	0.530

BioGRID (186): KRTAP5-9 (Two-hybrid), KRTAP10-9 (Two-hybrid), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Proximity Label-MS), SCARB1 (Proximity Label-MS), SCARB1 (Proximity Label-MS), SCARB1 (Affinity Capture-MS), SCARB1 (Affinity Capture-MS)

ESM2 similar proteins: A5A6J8, A5D7U4, O18824, O35114, O35409, P05026, P05027, P05028, P06583, P07340, P08251, P13638, P14094, P14231, P14415, P16671, P26201, P27615, P51168, P58421, P70110, P70627, P97943, Q07969, Q08857, Q14108, Q28030, Q2HZ96, Q4R4V5, Q4R5C3, Q5F362, Q5J583, Q5R8S8, Q60417, Q61009, Q6P9A2, Q708S3, Q708S7, Q7T2D4, Q8L8W0

Diamond homologs: O18824, O35114, P16671, P26201, P27615, P70110, P97943, Q07969, Q08857, Q14108, Q27367, Q60417, Q61009, Q8SQC1, Q8WTV0, Q11124, Q55FQ9, Q9BKJ9, Q9XYS8, E1JI63, C3U0S3, P86905, B2RFN2, Q7Q6R1, B7Z031

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
SCARB1	“up-regulates activity”	SRC	binding

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 105 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Interferon gamma signaling	7	12.4×	2e-04
Downstream TCR signaling	5	9.0×	3e-03
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell	6	7.4×	2e-03
MHC class II antigen presentation	5	6.3×	9e-03
Neutrophil degranulation	11	3.6×	3e-03

GO biological processes:

GO term	Partners	Fold	FDR
peptide antigen assembly with MHC class II protein complex	5	56.6×	1e-05
antigen processing and presentation of exogenous peptide antigen via MHC class II	5	29.2×	2e-04
positive regulation of T cell mediated cytotoxicity	5	27.5×	2e-04
positive regulation of immune response	5	25.9×	2e-04
positive regulation of T cell activation	5	23.8×	3e-04
ERAD pathway	5	9.7×	9e-03
adaptive immune response	8	7.2×	1e-03
immune response	11	5.6×	5e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

204 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	1
Likely pathogenic	0
Uncertain significance	83
Likely benign	66
Benign	36

Top pathogenic / likely-pathogenic (1)

Variant ID	HGVS	Classification
1334398	NM_005505.5(SCARB1):c.727-2A>C	Pathogenic

SpliceAI

2682 predictions. Top by Δscore:

Variant	Effect	Δscore
12:124778585:CC:C	acceptor_gain	1.0000
12:124778586:CC:C	acceptor_gain	1.0000
12:124786355:A:AC	donor_gain	1.0000
12:124786356:C:CC	donor_gain	1.0000
12:124786356:CTTGG:C	donor_gain	1.0000
12:124786499:CCGCT:C	acceptor_gain	1.0000
12:124786500:CGCT:C	acceptor_gain	1.0000
12:124786500:CGCTC:C	acceptor_gain	1.0000
12:124786502:CT:C	acceptor_gain	1.0000
12:124787405:CCT:C	donor_gain	1.0000
12:124807759:A:AC	donor_gain	1.0000
12:124807760:C:CC	donor_gain	1.0000
12:124807760:CTGAA:C	donor_gain	1.0000
12:124811864:CCTCA:C	donor_loss	1.0000
12:124811865:CTCA:C	donor_loss	1.0000
12:124811866:TCACC:T	donor_loss	1.0000
12:124811867:CACC:C	donor_loss	1.0000
12:124811868:ACCT:A	donor_loss	1.0000
12:124811869:C:A	donor_loss	1.0000
12:124811869:CCTTG:C	donor_gain	1.0000
12:124811965:GCTA:G	acceptor_loss	1.0000
12:124811966:C:CC	acceptor_gain	1.0000
12:124811967:T:G	acceptor_loss	1.0000
12:124814197:CGTA:C	donor_loss	1.0000
12:124814200:ACCTC:A	donor_loss	1.0000
12:124814201:CCT:C	donor_gain	1.0000
12:124814401:GCACC:G	acceptor_gain	1.0000
12:124814402:CACC:C	acceptor_gain	1.0000
12:124814402:CACCC:C	acceptor_gain	1.0000
12:124814403:ACC:A	acceptor_gain	1.0000

AlphaMissense

3384 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
12:124807810:G:C	F320L	0.999
12:124807810:G:T	F320L	0.999
12:124807812:A:G	F320L	0.999
12:124810174:C:G	R281P	0.999
12:124817666:C:A	W56C	0.999
12:124817666:C:G	W56C	0.999
12:124817668:A:G	W56R	0.999
12:124817668:A:T	W56R	0.999
12:124795224:G:C	S391R	0.998
12:124795224:G:T	S391R	0.998
12:124795226:T:G	S391R	0.998
12:124795261:C:T	G379E	0.998
12:124810249:C:T	G256E	0.998
12:124810278:C:A	W246C	0.998
12:124810278:C:G	W246C	0.998
12:124800225:A:G	S343P	0.997
12:124810249:C:A	G256V	0.997
12:124810280:A:G	W246R	0.997
12:124810280:A:T	W246R	0.997
12:124811926:C:A	G224W	0.997
12:124807871:C:G	R300P	0.996
12:124810232:A:G	W262R	0.996
12:124810232:A:T	W262R	0.996
12:124815065:A:G	S112P	0.996
12:124795261:C:A	G379V	0.995
12:124807811:A:C	F320C	0.995
12:124807811:A:G	F320S	0.995
12:124807847:A:C	F308C	0.995
12:124807867:G:C	F301L	0.995
12:124807867:G:T	F301L	0.995

dbSNP variants (sampled 300 via entrez): RS1000071346 (12:124776754 C>T), RS1000087143 (12:124820329 A>G), RS1000113702 (12:124844529 G>A,T), RS1000118237 (12:124820078 G>A), RS1000191070 (12:124793509 T>C,G), RS1000210253 (12:124835043 T>C), RS1000224412 (12:124838203 C>G), RS1000295721 (12:124845998 C>T), RS1000299400 (12:124838491 G>A), RS1000322657 (12:124798216 G>A,C), RS1000354923 (12:124812735 C>T), RS1000490707 (12:124827730 C>A,G), RS1000532925 (12:124856801 G>A,C), RS1000534197 (12:124786879 C>A), RS1000569502 (12:124780347 T>C)

Disease associations

OMIM: gene MIM:601040 | disease phenotypes: MIM:189800

GenCC curated gene-disease

Mondo (2): preeclampsia (MONDO:0005081), primary ovarian failure (MONDO:0005387)

Orphanet (2): Preeclampsia (Orphanet:275555), NON RARE IN EUROPE: Primary ovarian failure (Orphanet:619)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

66 associations (top):

Study	Trait	p-value
GCST000671_5	Lipoprotein-associated phospholipase A2 activity and mass	1.000000e-08
GCST000755_41	HDL cholesterol	3.000000e-14
GCST000907_1	Renal cell carcinoma	3.000000e-08
GCST001142_3	Vitamin E levels	8.000000e-09
GCST001727_2	Lipoprotein-associated phospholipase A2 activity and mass	6.000000e-14
GCST002223_51	HDL cholesterol	6.000000e-32
GCST002899_39	HDL cholesterol	2.000000e-18
GCST003445_1	Response to cyclophosphamide in systemic lupus erythematosus with lupus nephritis	6.000000e-07
GCST004232_9	HDL cholesterol levels	1.000000e-34
GCST004787_55	Coronary artery disease (myocardial infarction, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease)	4.000000e-09
GCST004963_7	Lipoprotein phospholipase A2 activity in cardiovascular disease	7.000000e-09
GCST005194_45	Coronary artery disease	2.000000e-13
GCST005194_46	Coronary artery disease	2.000000e-08
GCST005195_128	Coronary artery disease	2.000000e-18
GCST005196_72	Coronary artery disease	3.000000e-20
GCST005980_2	Total bilirubin levels	4.000000e-11
GCST006005_22	High density lipoprotein cholesterol levels	1.000000e-32
GCST006034_24	Total cholesterol levels	6.000000e-09
GCST006481_19	Lung function (FEV1)	5.000000e-08
GCST006611_100	HDL cholesterol	8.000000e-43
GCST006613_116	Triglycerides	3.000000e-14
GCST007827_1	Alzheimer’s disease or HDL levels (pleiotropy)	4.000000e-09
GCST007931_66	Medication use (HMG CoA reductase inhibitors)	2.000000e-08
GCST008035_78	High density lipoprotein cholesterol levels	4.000000e-09
GCST008070_118	HDL cholesterol levels	3.000000e-20
GCST008070_51	HDL cholesterol levels	2.000000e-24
GCST008075_148	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	7.000000e-44
GCST008075_208	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	1.000000e-24
GCST008075_33	HDL cholesterol levels x alcohol consumption (regular vs non-regular drinkers) interaction (2df)	7.000000e-19
GCST008084_153	HDL cholesterol levels x alcohol consumption (drinkers vs non-drinkers) interaction (2df)	8.000000e-49

EFO canonical traits (17, from GWAS)

EFO ID	Trait name
EFO:0004746	lipoprotein-associated phospholipase A(2) measurement
EFO:0004612	high density lipoprotein cholesterol measurement
EFO:0004570	bilirubin measurement
EFO:0004574	total cholesterol measurement
EFO:0004314	forced expiratory volume
EFO:0004530	triglyceride measurement
EFO:0009932	HMG CoA reductase inhibitor use measurement
EFO:0004329	alcohol drinking
EFO:0004611	low density lipoprotein cholesterol measurement
EFO:0004614	apolipoprotein A 1 measurement
EFO:0004615	apolipoprotein B measurement
EFO:0004527	mean corpuscular hemoglobin
EFO:0005091	monocyte count
EFO:0007989	monocyte percentage of leukocytes
EFO:0007874	gut microbiome measurement
EFO:0007788	BMI-adjusted waist-hip ratio
EFO:0008039	BMI-adjusted hip circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D011225	Pre-Eclampsia	C12.050.703.395.249
D016649	Primary Ovarian Insufficiency	C12.050.351.500.056.630.750; C12.100.250.056.630.750; C19.391.630.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (1): CHEMBL1914272 (SINGLE PROTEIN)

Molecules with ChEMBL bioactivity

2 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 1,146 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL1208829	ITX-5061 FREE BASE	2	98
CHEMBL275707	RIMCAZOLE	2	1,048

PharmGKB: 1 entry (VIP=true, CPIC=false)

PharmGKB clinical annotations

3 annotations.

Variant	Type	Level	Drugs	Phenotypes
rs10846744	Efficacy	3	peginterferon alfa-2a;ribavirin	Chronic hepatitis C virus infection
rs4238001	Efficacy	3	fenofibrate	Hypertriglyceridemia
rs5888	Efficacy	3	atorvastatin	Hypercholesterolemia

PharmGKB variants

4 variants.

Variant	Genes	Level	Score	#Clin annots	Drugs
rs5888	SCARB1	3	2.75	1	atorvastatin
rs4238001	SCARB1	3	3.50	1	fenofibrate
rs10846744	SCARB1	3	2.50	1	peginterferon alfa-2a;ribavirin
rs3782287	SCARB1		0.00	0

ChEMBL bioactivities

54 potent at pChembl≥5 of 54 total, top 50 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
8.82	IC50	1.5	nM	CHEMBL2179510
8.82	IC50	1.5	nM	CHEMBL2179485
8.82	IC50	1.5	nM	CHEMBL2179515
8.82	IC50	1.5	nM	CHEMBL2179514
8.82	IC50	1.5	nM	CHEMBL2179511
8.82	IC50	1.5	nM	CHEMBL2179509
8.82	IC50	1.5	nM	CHEMBL2179508
8.82	IC50	1.5	nM	CHEMBL2179507
8.82	IC50	1.5	nM	CHEMBL2179504
8.82	IC50	1.5	nM	CHEMBL2179502
8.82	IC50	1.5	nM	CHEMBL2179501
8.82	IC50	1.5	nM	CHEMBL2179500
8.82	IC50	1.5	nM	CHEMBL2179499
8.82	IC50	1.5	nM	CHEMBL2179493
8.82	IC50	1.5	nM	CHEMBL1914885
8.30	IC50	5	nM	CHEMBL2179106
8.30	IC50	5	nM	CHEMBL2179512
8.30	IC50	5	nM	CHEMBL2179497
8.00	IC50	10	nM	CHEMBL2179488
7.82	IC50	15	nM	CHEMBL2179487
7.82	IC50	15	nM	CHEMBL2179486
7.82	IC50	15	nM	CHEMBL2179513
7.82	IC50	15	nM	CHEMBL2179506
7.82	IC50	15	nM	CHEMBL2179498
7.82	IC50	15	nM	CHEMBL2177128
7.82	IC50	15	nM	CHEMBL2179494
7.52	IC50	30	nM	CHEMBL2179490
7.40	IC50	39.81	nM	CHEMBL3785336
7.30	IC50	50	nM	CHEMBL2179505
7.30	IC50	50	nM	CHEMBL2179503
7.30	IC50	50	nM	CHEMBL2179496
7.30	IC50	50	nM	CHEMBL2179495
7.30	IC50	50	nM	CHEMBL2179492
7.30	IC50	50	nM	CHEMBL2179489
7.30	IC50	50.12	nM	CHEMBL3786653
7.30	IC50	50.12	nM	CHEMBL3785828
7.30	IC50	50.12	nM	CHEMBL3785750
7.30	IC50	50.12	nM	CHEMBL3787085
7.10	IC50	79.43	nM	CHEMBL3785219
7.00	IC50	100	nM	ITX-5061 FREE BASE
6.80	IC50	158.5	nM	CHEMBL3786659
6.80	IC50	158.5	nM	CHEMBL3786730
6.70	IC50	199.5	nM	CHEMBL3785530
6.64	IC50	230	nM	CHEMBL1914861
6.30	IC50	500	nM	CHEMBL2179491
6.30	IC50	501.2	nM	CHEMBL3787449
6.22	IC50	600	nM	CHEMBL1914862
6.20	IC50	630	nM	CHEMBL1914863
6.00	IC50	1000	nM	CHEMBL3786485
6.00	IC50	1000	nM	CHEMBL3786591

PubChem BioAssay actives

54 with measured affinity, of 62 total; 50 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
methyl 9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazole-3-carboxylate	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
2-[9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-1,3-oxazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-(tetrazol-1-yl)-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(3,5-difluorophenoxy)propyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(3,4-difluorophenoxy)propyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(3,5-difluorophenyl)sulfanylpropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704911: Inhibition of human SRB1-mediated Hepatitis C virus genotype 1a entry into human HuH7.5 cells by immunoblotting	ic50	0.0015	uM
5-[9-[3-(3,4-difluorophenyl)sulfanylpropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(6-fluoro-1H-benzimidazol-2-yl)propyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(3,5-difluorophenoxy)-2-fluoropropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-carbazol-4-one	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
3-methyl-5-[9-[3-[4-methyl-6-(trifluoromethyl)pyrimidin-2-yl]oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
N,N-dimethyl-3-[6-(3-methyl-1,2,4-oxadiazol-5-yl)-1,2,3,4-tetrahydrocarbazol-9-yl]propane-1-sulfonamide	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-nitro-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0015	uM
5-[9-[3-(3,5-difluorophenyl)sulfonylpropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0050	uM
9-[3-(3,5-difluorophenyl)sulfanylpropyl]-6-(3-methyl-1,2,4-oxadiazol-5-yl)-2,3-dihydro-1H-carbazol-4-one	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0050	uM
3-[9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-5-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0050	uM
4,6-dimethoxy-N-[3-(6-methylsulfonyl-1,2,3,4-tetrahydrocarbazol-9-yl)propyl]pyrimidin-2-amine	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0100	uM
9-[3-[(4,6-dimethoxypyrimidin-2-yl)amino]propyl]-5,6,7,8-tetrahydrocarbazole-3-carbonitrile	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-(4-propyltriazol-1-yl)-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
5-[9-[3-(3,5-difluorophenyl)sulfinylpropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
5-[9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6,6-difluoro-7,8-dihydro-5H-carbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
5-[9-[3-(3,5-difluorophenyl)sulfanylpropyl]-6,6-difluoro-7,8-dihydro-5H-carbazol-3-yl]-3-methyl-1,2,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazole-3-carbonitrile	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
2-[9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-5-methyl-1,3,4-oxadiazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0150	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-methylsulfonyl-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0300	uM
N-[3-[3-[bis(2-hydroxyethyl)amino]propylsulfonylamino]-5-tert-butyl-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0398	uM
3-(6-cyano-1,2,3,4-tetrahydrocarbazol-9-yl)-N,N-dimethylpropane-1-sulfonamide	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-6-methylsulfonyl-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
2-[9-[3-(4,6-dimethylpyrimidin-2-yl)oxypropyl]-5,6,7,8-tetrahydrocarbazol-3-yl]-4,5-dihydro-1,3-oxazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
9-[3-(4,6-diethylpyrimidin-2-yl)oxypropyl]-6-[4-(fluoromethyl)triazol-1-yl]-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
9-[3-(1H-benzimidazol-2-yl)propyl]-6-methylsulfonyl-1,2,3,4-tetrahydrocarbazole	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
9-[3-(1H-benzimidazol-2-yl)propyl]-5,6,7,8-tetrahydrocarbazole-3-carbonitrile	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.0500	uM
N-[5-tert-butyl-3-[3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]propylsulfonylamino]-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0501	uM
N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(4-morpholin-4-ylbutoxy)naphthalen-1-yl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0501	uM
2-[4-[2-[(2-aminoacetyl)amino]ethoxy]naphthalen-1-yl]-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0501	uM
N-[5-tert-butyl-2-methoxy-3-(propylsulfonylamino)phenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0501	uM
2-[4-[2-[bis(2-hydroxyethyl)amino]ethoxy]naphthalen-1-yl]-N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.0794	uM
N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.1000	uM
3-[[5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]phenyl]sulfamoyl]propyl-triethylazanium;2,2,2-trifluoroacetate	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.1585	uM
N-[3-(4-aza-1-azoniabicyclo[2.2.2]octan-1-ylmethylsulfonylamino)-5-tert-butyl-2-methoxyphenyl]-2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetamide chloride	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.1585	uM
2-[[5-tert-butyl-2-methoxy-3-[[2-[4-(2-morpholin-4-ylethoxy)naphthalen-1-yl]-2-oxoacetyl]amino]phenyl]sulfamoyl]acetic acid	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.1995	uM
methyl 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole-3-carboxylate	630155: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human 293T cells by immunoblotting	ic50	0.2300	uM
N,N-dimethyl-3-(6-methylsulfonyl-1,2,3,4-tetrahydrocarbazol-9-yl)propane-1-sulfonamide	704937: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human HuH7.5 cells by luciferase reporter gene assay	ic50	0.5000	uM
2-[4-[2-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyanilino]-2-oxoacetyl]naphthalen-1-yl]oxyethyl-trimethylazanium;2,2,2-trifluoroacetate	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	0.5012	uM
ethyl 9-[3-[(3R,5S)-3,5-dimethylpiperazin-1-yl]propyl]carbazole-3-carboxylate	630155: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human 293T cells by immunoblotting	ic50	0.6000	uM
propan-2-yl 9-[3-[(3S,5R)-3,5-dimethylpiperazin-1-yl]propyl]carbazole-3-carboxylate	630155: Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human 293T cells by immunoblotting	ic50	0.6300	uM
N-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyphenyl]-2-[4-[2-(4-methylmorpholin-4-ium-4-yl)ethoxy]naphthalen-1-yl]-2-oxoacetamide;2,2,2-trifluoroacetate	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	1.0000	uM
3-[2-[4-[2-[5-tert-butyl-3-(methanesulfonamido)-2-methoxyanilino]-2-oxoacetyl]naphthalen-1-yl]oxyethylamino]-3-oxopropanoic acid	1291805: Inhibition of human SR-B1 transiently expressed in human U2OS cells assessed as Dil-HDL uptake preincubated for 2 hrs followed by Dil-HDL addition measured after 2 hrs by FLIPR assay	ic50	1.0000	uM

CTD chemical–gene interactions

121 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Cyclosporine	affects cotreatment, decreases expression	4
Resveratrol	decreases expression, decreases reaction, affects cotreatment, increases expression	3
Aspirin	affects expression, affects cotreatment, increases expression, decreases reaction, decreases activity (+2 more)	3
Benzo(a)pyrene	affects methylation, decreases expression, increases methylation	3
Estradiol	decreases reaction, increases expression	3
Valproic Acid	affects expression, decreases expression, increases expression, increases methylation	3
Particulate Matter	increases expression, decreases expression, increases abundance	3
bisphenol A	affects expression, decreases methylation	2
cobaltous chloride	decreases expression	2
perfluorooctanoic acid	decreases expression	2
entinostat	increases expression, affects cotreatment	2
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	decreases expression, increases expression, affects cotreatment	2
Rosiglitazone	affects cotreatment, increases expression	2
Air Pollutants	decreases expression, increases abundance	2
Chenodeoxycholic Acid	increases expression, affects cotreatment, decreases expression	2
Cisplatin	decreases expression, affects cotreatment, increases expression	2
Deoxycholic Acid	affects cotreatment, decreases expression, increases expression	2
Ethinyl Estradiol	decreases expression, increases reaction, affects expression, affects splicing, affects cotreatment	2
Hydrocortisone	affects cotreatment, decreases expression, decreases reaction	2
Niacin	increases reaction, decreases reaction, increases expression, increases export	2
Nickel	decreases expression	2
Tobacco Smoke Pollution	decreases reaction, affects binding, increases reaction, affects localization, increases expression (+2 more)	2
Tretinoin	decreases expression	2
Aflatoxin B1	affects expression, decreases expression	2
FR900359	decreases phosphorylation	1
dicrotophos	increases expression	1
selenomethylselenocysteine	increases expression	1
diphenyleneiodonium	decreases expression, decreases reaction	1
ascorbate-2-phosphate	affects binding, affects cotreatment, increases expression	1
diethyl maleate	decreases expression	1

ChEMBL screening assays

4 unique, capped per target: 4 binding

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1918056	Binding	Inhibition of human SRB1-mediated Hepatitis C virus genotype 2a entry into human 293T cells by immunoblotting	Discovery of highly potent small molecule Hepatitis C Virus entry inhibitors. — Bioorg Med Chem Lett

Cellosaurus cell lines

11 cell lines: 5 cancer cell line, 2 transformed cell line, 2 spontaneously immortalized cell line, 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B7Z9	Abcam Raji SCARB1 KO	Cancer cell line	Male
CVCL_B9W5	Abcam HEK293T SCARB1 KO	Transformed cell line	Female
CVCL_C0A2	Abcam THP-1 SCARB1 KO	Cancer cell line	Male
CVCL_C7BQ	Abcam PC-3 SCARB1 KO	Cancer cell line	Male
CVCL_E8TM	CHO-SR-B1	Spontaneously immortalized cell line	Female
CVCL_E8TN	CHO-CD81/SR-B1	Spontaneously immortalized cell line	Female
CVCL_E8TP	293-SR-B1	Transformed cell line	Female
CVCL_EL59	PENN159i-M14-4	Induced pluripotent stem cell	Female
CVCL_EL62	PENN162i-M14-11	Induced pluripotent stem cell	Female
CVCL_TK10	HAP1 SCARB1 (-) 1	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial